Similar drugsTo uncover Dosage form: & nbspnasal drops. Composition:Selanka in terms of 100% substance - 1.5 mg (threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline diacetate)methylparahydroxybenzoate (nipagine) 1 mgpurified water - up to 1ml. Description:Colorless transparent liquid. Pharmacotherapeutic group:anxiolytic (tranquilizer). ATX: & nbspAnxiolytics Pharmacodynamics:Selanc® is a synthetic analogue of the endogenous peptide taftcin, has an original mechanism of neurospecific action on the central nervous system, binds to specific receptors on the membranes of nerve cells.Has an effect on the exchange of monoamines in the emotionogenic structures of the brain (hypothalamus, diencephalon, hemispherical cortex) and the activity of brain enzymes of tyrosine and tryptophan hydroxylase. It shows tropicity to the serotonergic system, normalizing the serotonin level of the brain under the conditions of experimentally caused its decrease. Selanc® stabilizes the processes of excitation and inhibition in the brain and increases the stability of neurons of the cerebral cortex to functional loads of high intensity.In the spectrum of the pharmacological action of the drug, an anxiolytic (counter-anxiety) effect with a stimulating (activating) component predominates. The drug does not possess hypnotic and muscle relaxant properties.Positively affects the mnestic and cognitive functions of the brain, including their violation. Activates the learning, memory, analysis and playback of information, improves attention and short-term memory. Increases the motivational stability and adequacy of adaptive behavior. Selank® has a vegetotrophic effect, improves the vegetative maintenance of activity in conditions of emotional stress, it has an optimizing effect on the adaptive reserve of the organism. Selank® does not reveal undesirable side effects and toxic effects at a 200-300-fold increase in dose compared with ED50. Does not have embryotoxic, teratogenic, allergic, local irritant effect, does not show mutagenic properties. The drug has no undesirable long-term effects.Selanc® does not cause drug dependence. Pharmacokinetics:Absolute bioavailability of Selanc® with intranasal administration is 92.8%. The drug is rapidly absorbed from the nasal mucosa and after 30 seconds is detected in the blood plasma. Concentration in the blood plasma progressively decreases within 5-5.5 minutes.Metabolites with intranasal route of administration are not detected. Penetrates into the brain tissue. The drug is quickly distributed to organs and tissues, is found unchanged in well-vascularized organs (liver, kidneys, heart). In daily urine, neither unchanged drug nor metabolites are determined, which is due to the rapid degradation of Selanc® under the influence of tissue peptidases. Indications:It is used in adults with anxiety and anxiety-asthenic disorders, corresponding to the diagnostic criteria of generalized anxiety disorders, neurasthenia, adaptation disorders. Contraindications:Pregnancy, lactation. Individual intolerance to the drug. Dosing and Administration:Selanc is administered intranasally using a vial of a dropper.Carefully cut off the tip of the pipette at the location shown in Fig. 1.The cap should close the pipette tightly - Fig. 2.Turn the bottle and, tapping lightly on the bottom, wait for the liquid to fill the entire space of the pipette - Fig. 3.Remove the cap and lightly pressing on the wide part of the pipette, squeeze the required number of drops of the drug into the nasal passage (on the mucous membrane) - Fig. 4.Instillation of the drug in the nasal passages is carried out in the sitting position of the patient with a slightly thrown head, after which for a short time the finger is clamped by each nostril. The effectiveness of absorption can be reduced in the presence of increased secretions of the nasal mucosa. At a time, no more than 2-3 drops are injected into each nostril, which is 300 μg (4 drops - 0.2 ml) - 450 μg (6 drops - 0.3 ml). To increase the dose of a single dose, repeated administration of the drug is carried out after 15 minutes. The optimal single doses - 300-900 mcg (4-12 drops), daily - 900-2700 mcg (12-36 drops), distributed on 3 doses during the day. The duration of the course use of the drug is 10-14 days. If necessary, the course of treatment can be repeated in 1-3 weeks. Side effects:With increased sensitivity to the perception of odor and taste, if the preparation gets from the nasal cavity to the mucous membrane of the pharynx, unpleasant gustatory sensations may appear. Perhaps the development of allergic reactions with individual intolerance. Overdose:With the use of Selanca®, due to the rapid degradation of the drug, overdose and intoxication are not observed. Interaction:Selanc® does not affect the effects of drugs that depress and stimulate the central nervous system - haloperidol, pentobarbital, hexobarbital, analeptics. Special instructions:The lack of hypnose-sedative and muscle relaxant properties and the presence of a positive effect on cognitive functions make it possible to use Selanc® in people of various professions, including those requiring increased attention and coordination of movements (drivers of vehicles, operators, etc.). Form release / dosage:Nasal drops of 0.15%. Packaging:To 3 ml in a glass bottle sealed with a plastic stopper pipette, or in a glass bottle sealed with a plastic screw cap with the attached pipette with a lid. Each vial with instruction for use is packaged in a pack of cardboard. Storage conditions:List B. In the dark place at a temperature of not more than +10 ° C, do not allow freezing. Keep out of the reach of children. Shelf life:2 years. Do not use after the time specified on the package. Terms of leave from pharmacies:On prescription Registration number:LSR-003338/09 Date of registration:30.04.2009 / 11.08.2015 The owner of the registration certificate:Peptogen Innovative Research and Production Center, ZAO Peptogen Innovative Research and Production Center, ZAO Russia Manufacturer: & nbspPeptogen Innovative Research and Production Center, ZAO Russia Information update date: & nbsp2016-02-14 Illustrated instructions × Illustrated instructions Instructions